Actions
Washington
,
US
15 November 2026
Obesity Week (OW 2026)
Presentation schedule and materials
Saturday, 14 November 2026
19:30
- 20:30
EST
POSTER
Impact of Oral Semaglutide 25 mg on Patient-Reported Daily Activities: IWDAQ Outcomes from OASIS 4
Domenica Rubino1; Oscar Birkhan2; Silvia Gasparroni2; Lisa von Huth Smith2; Agnieszka Klimek-Abercrombie2; Megha Poddar3
MATERIALS AVAILABLE
Coming soon
19:30
EST
POSTER
Effect of CagriSema according to baseline BMI and obesity-related complications: REDEFINE 1 trial
W. Timothy Garvey1; Jaime P. Almandoz2; Mikkel Hovden Christensen3/sup>; Tobias Freyberg Justesen3; Domenica Rubino4; Kirsi H. Pietiläinen5; Arya M. Sharma6; Kasper Adelborg3; John P.H. Wilding7
MATERIALS AVAILABLE
Coming soon
19:30
- 20:30
EST
POSTER
Impact of Cagrilintide 2.4 mg on Cardiometabolic Risk Indicators:a Post-hoc Analysis of REDEFINE 1
W. Timothy Garvey1; Rikke Mortensen Abschneider2; Morten Böttcher3; Dana Li2; Kasper Adelborg2; John Wilding4;, Ildiko Lingvay5;
MATERIALS AVAILABLE
Coming soon
Sunday, 15 November 2026
08:30
- 08:45
EST
ORAL PRESENTATION
Effects of CagriSema on Physical and Psychosocial Function in Overweight or Obesity: REDEFINE 1
Domenica Rubino1; Kirsi H. Pietiläinen2; Arya M. Sharma3; Subodh Verma4; Sean Wharton5; Julie Hviid Hahn-Pedersen6; Tobias Freyberg Justesen6;, Lisa von Huth Smith6; Niels Zeuthen6; Ronette L. Kolotkin7-10;7
MATERIALS AVAILABLE
Coming soon
14:30
- 15:30
EST
POSTER
Cagrilintide’s Potential Benefits on Bone Health via Proteomics in Adults With Over-Weight or Obesity
Anne-Mette Bjerregaard1; Jonas Andreas Sibbesen1; Kristian Ebbesen Hanghøj1; Marco Ponzetti2;, Dana Li3; Christoffer Andersen Hagemann4; Anna Secher2; Kirsten Raun2; David H Ipsen2
MATERIALS AVAILABLE
Coming soon
14:30
- 15:30
EST
POSTER
Early Response and Weight Loss Trajectories With CagriSema in Overweight or Obesity: REDEFINE 1
Kirsi H. Pietiläinen1; Jaime Almandoz2; Mikkel Hovden Christensen3; Cynthia Karenina Osorto Contreras3; Thomas Bo Jensen3; Michael G. Knight4; Ricardo Arturo Reynoso Mendoza5; Carel W. le Roux6,7; W. Timothy Garvey8;
MATERIALS AVAILABLE
Coming soon
14:30
EST
POSTER
REDEFINE 9: Effect of CagriSema 1.7 mg/1.7 mg and 1.0 mg/1.0 mg in Adults With Overweight or Obesity
Sean Wharton1,2; Christa Broholm3; Deborah Horn4; Alexandru-Remus Pinţa3; Domenica Rubino5; Zara Rebecca Broholm3; Stephen Bain66;
MATERIALS AVAILABLE
Coming soon
14:30
- 15:30
EST
POSTER
AWS Cloud–First Data Discovery for Pragmatic Clinical Trial Linkage
Thomas Dougherty1; Helene Nordahl1; Matt Witman2; Anala Gossai2; Kathleen M. Gavin2
MATERIALS AVAILABLE
Coming soon
16:00
- 16:15
EST
ORAL PRESENTATION
Effect of Cagrilintide 2.4 mg on food cravings and eating behavior: REDEFINE 1 post hoc analysis
Michelle Dalton1; Rikke M. Abschneider2; Thomas L. Holm2; Dana Li2; Kirsi H. Pietiläinen3; Domenica Rubino4; Thomas Wadden5; Matthias Blüher6
MATERIALS AVAILABLE
Coming soon
18:30
- 19:45
EST
Symposium
Obesity in Focus: Today's evidence. Tomorrow's possibilities
Jaime Almandoz
;
Deborah Bade Horn
;
Akshay Jain
;
Thomas Lutz
;
Domenica Rubino
MATERIALS AVAILABLE
Actions
Keywords